Navigation Links
JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
Date:9/6/2012

FORT BELVOIR, Va., Sept. 6, 2012 /PRNewswire-USNewswire/ -- A contract to evaluate an alternative method for delivering a medical countermeasure (MCM) was awarded to Sarepta Therapeutics by the Joint Project Manager Transformational Medical Technologies (JPM-TMT).  A component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), JPM-TMT has made significant progress in the development of a therapeutic to fight the highly lethal Marburg virus.  During the course of developing the drug candidate thus far, the intravenous (IV) method of delivery is being utilized.  This new $3.9 million contract will evaluate the feasibility of an intramuscular (IM) route, a more practical administration of a drug.

(Logo: http://photos.prnewswire.com/prnh/20120315/DC71198LOGO)

John Anderson, Product Manager of JPM-TMT's Hemorrhagic Fever Virus-Therapeutics Medical Countermeasures acquisition program, commented on the development of the drug candidate. "With AVI-7288 showing survival rates up to four days post infection, we are eager to determine whether it is feasible to deliver a drug intramuscularly—a route that could reduce the logistical burden of administering the medical countermeasure to our Warfighter. IM delivery is both easier and quicker to administer.  The IV route takes up to one hour while IM administration takes just seconds. The potential for efficient treatment in a mass casualty situation is obvious."

There is no treatment for infection caused by Marburg virus, a member of the Filoviridae family of Hemorrhagic Fever Viruses (HFV).  The disease is characterized by high fever, chills, nausea, vomiting, chest pain, diarrhea, and in some cases, massive hemorrhaging and organ dysfunction. 

"Developing a treatment for the highly lethal Marburg virus infection is ground-breaking," said David E. Hough, Joint Project Manager for JPM-TMT. "JPM-TMT is the only U.S. government agency testing a post-exposure drug candidate against this dangerous disease. Our goal is to successfully develop a therapeutic for the Marburg virus infection using platform technologies that will ultimately have the capacity to rapidly respond to outbreaks of all HFVs as well as other biological pathogens. Both our Warfighters and the nation stand to benefit from our unique approach."

Joint Project Manager Transformational Medical Technologies (JPM-TMT)

JPM-TMT is a component of the U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). JPM-TMT aims to protect the Warfighter from emerging infectious diseases, genetically altered, and unknown biological threats. Through strategic investments and partnerships with innovative biotech firms, pharmaceutical corporations, other government agencies, and academic institutions, JPM-TMT facilitates the advanced development and acquisition of adaptable platform technologies, broad-spectrum medical countermeasures, and innovative systems to enhance our nation's biodefense response capability. For more information, visit www.jpmtmt.mil.


'/>"/>
SOURCE Joint Project Manager Transformational Medical Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
2. Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
3. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
4. The Masonry Heater Association of North America Announces the 2012 Masonry Heater, Bake Oven and Masonry Project Awards
5. picoSpin-45 Benchtop NMR Spectrometer a Finalist in the European Life Sciences Awards
6. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
7. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
8. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
9. The Scientist Magazine’s 2012 Multimedia Awards—Call for Entries
10. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
11. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... Virginia (PRWEB) , ... February 06, 2016 , ... ... E-mail: amitchell(at)cee(dot)org , The Center for Excellence in Education Sponsors Teacher Training ... VA – February 4, 2016 – The Center for Excellence in Education (CEE) ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... Falls Church, VA (PRWEB) , ... ... ... a first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes ... Bloomsburg, PA. The two-day event features 20+ speakers and activities such as ...
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):